The invention relates to improved aqueous pharmaceutical compositions of a recombinant monoclonal antibody to TNFα, and to a method for producing same. The present invention also relates to the use of improved aqueous pharmaceutical compositions of a recombinant monoclonal antibody to TNFα to treat TNFα-mediated diseases. The proposed invention allows prevention of physical-chemical instability expressed in the formation of aggregates and fragments of proteins or in the modification of proteins in a solution, and also prevents instability during freezing/thawing, agitating and shaking.
